On Air Now

Listen

Listen Live Now » 101.9 FM Central Wisconsin

Weather

Current Conditions(Wausau,WI 54403)

More Weather »
65° Feels Like: 65°
Wind: W 6 mph Past 24 hrs - Precip: 0.01”
Current Radar for Zip

Tonight

Mostly Clear 53°

Tomorrow

Mostly Sunny 75°

Wed Night

Clear 53°

Alerts

Bayer's regorafenib gets priority review by FDA

FRANKFURT (Reuters) - U.S. health regulators granted a priority review for Bayer's cancer drug regorafenib for the treatment of gastrointestinal stromal tumors, potentially speeding up the treatment's route to market.

The U.S. Food and Drug Administration grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies.

A priority review takes six months rather than the usual 10 to 12-months.

Onyx Pharmaceuticals is the U.S. marketing partner for regorafenib, which will be branded as Stivarga.

(Reporting by Ludwig Burger)

Comments